Data Insights

Fruquintinib by Takeda Pharmaceutical for Rectal Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Rectal Cancer

Data Insights

Fruquintinib by Takeda Pharmaceutical for Endometrial Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Endometrial Cancer

Data Insights

Fruquintinib by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Solid Tumor

Data Insights

Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Angiosarcoma

Data Insights

Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Metastatic Pancreatic Cancer

Data Insights

Fruquintinib by Takeda Pharmaceutical for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Data Insights

Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Data Insights

Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...